Literature DB >> 20450377

Human T-lymphotropic virus type I or II (HTLV-I/II) associated with recurrent longitudinally extensive transverse myelitis (LETM): two case reports.

Silvia R Delgado1, William A Sheremata, Andrew D Brown, Micheline McCarthy.   

Abstract

We describe two patients with recurrent longitudinally extensive transverse myelitis (LETM) associated with human T-lymphotropic virus type I or II (HTLV-I/II) exposure, and with neuromyelitis optica (NMO) immunoglobulin G (IgG) antibody in one case. HTLV-I/II are well known retroviral agents of myelopathy and B-cell dysfunction in humans. NMO is an autoimmune, demyelinating disorder of the central nervous system (CNS), also linked to B-cell dysfunction. Therefore, the immunopathogenesis of NMO may in some cases be linked to human HTLV exposure. Awareness of a possible association with human retroviral exposure will contribute to the optimal diagnosis and management of patients presenting with LETM or NMO.

Entities:  

Mesh:

Year:  2010        PMID: 20450377     DOI: 10.3109/13550281003801493

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  24 in total

1.  Devic's neuromyelitis optica and HIV-1 infection.

Authors:  P Blanche; E Diaz; B Gombert; D Sicard; O Rivoal; A Brezin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-06       Impact factor: 10.154

Review 2.  The HTLV-1 neurological complex.

Authors:  Abelardo Q C Araujo; Marcus Tulius T Silva
Journal:  Lancet Neurol       Date:  2006-12       Impact factor: 44.182

3.  Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial.

Authors:  S Izumo; I Goto; Y Itoyama; T Okajima; S Watanabe; Y Kuroda; S Araki; M Mori; S Nagataki; S Matsukura; T Akamine; M Nakagawa; I Yamamoto; M Osame
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

4.  HTLV-1 and polymyositis in Jamaica.

Authors:  O S Morgan; P Rodgers-Johnson; C Mora; G Char
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

5.  Spastic ataxia associated with human T-cell lymphotropic virus type II infection.

Authors:  W J Harrington; W Sheremata; B Hjelle; D K Dube; P Bradshaw; S K Foung; S Snodgrass; G Toedter; L Cabral; B Poiesz
Journal:  Ann Neurol       Date:  1993-04       Impact factor: 10.422

6.  Isolation of HTLV-II from a patient with chronic, progressive neurological disease clinically indistinguishable from HTLV-I-associated myelopathy/tropical spastic paraparesis.

Authors:  S Jacobson; T Lehky; M Nishimura; S Robinson; D E McFarlin; S Dhib-Jalbut
Journal:  Ann Neurol       Date:  1993-04       Impact factor: 10.422

Review 7.  Immunopathogensis of HTLV-I associated neurologic disease: molecular, histopathologic, and immunologic approaches.

Authors:  Norihiro Takenouchi; Karen Yao; Steven Jacobson
Journal:  Front Biosci       Date:  2004-09-01

Review 8.  Human T-lymphotropic virus type II and neurological disease.

Authors:  Abelardo Araujo; William W Hall
Journal:  Ann Neurol       Date:  2004-07       Impact factor: 10.422

9.  Abnormalities of spinal magnetic resonance images implicate clinical variability in human T-cell lymphotropic virus type I-associated myelopathy.

Authors:  Fujio Umehara; Hirohisa Nose; Mineki Saito; Michinari Fukuda; Mieko Ogino; Tomoko Toyota; Tomoaki Yuhi; Kimiyoshi Arimura; Mitsuhiro Osame
Journal:  J Neurovirol       Date:  2007-06       Impact factor: 2.643

10.  Human T lymphotropic virus type I-associated myelopathy. A report of 10 patients born in the United States.

Authors:  W A Sheremata; J R Berger; W J Harrington; D R Ayyar; M Stafford; E DeFreitas
Journal:  Arch Neurol       Date:  1992-11
View more
  3 in total

1.  Devastating aquaporin-4 and HTLV-1-associated necrotizing encephalopathy.

Authors:  Mkael Symmonds; Niranjanan Nirmalananthan; Graham P Taylor; Leslie R Bridges; Frederick Schon
Journal:  J Neurol       Date:  2012-08-24       Impact factor: 4.849

Review 2.  Longitudinal extensive transverse myelitis--it's not all neuromyelitis optica.

Authors:  Corinna Trebst; Peter Raab; Elke Verena Voss; Paulus Rommer; Mazen Abu-Mugheisib; Uwe K Zettl; Martin Stangel
Journal:  Nat Rev Neurol       Date:  2011-11-01       Impact factor: 42.937

3.  Aquaporin-4 immuneglobulin g testing in 36 consecutive jamaican patients with inflammatory central nervous system demyelinating disease.

Authors:  Sherri Sandy; Sean J Pittock; Terence A R Seemungal; Amza Ali
Journal:  Neurol Int       Date:  2014-08-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.